Cover Image
市場調查報告書

季節性流感- 開發中產品分析

Seasonal Influenza - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 264090
出版日期 內容資訊 英文 174 Pages
訂單完成後即時交付
價格
Back to Top
季節性流感- 開發中產品分析 Seasonal Influenza - Pipeline Review, H2 2015
出版日期: 2015年09月23日 內容資訊: 英文 174 Pages
簡介

季節性流感是流感病毒所造的急性病毒感染症。常出現突然的高燒、咳嗽(通常是乾咳)、頭痛、肌肉或關節痛、不適、喉嚨痛、鼻水等症狀,多數患者沒有特定治療即可在一星期之內回復。但具有高風險的人一旦感染則會呈現嚴重症狀,甚至有致死的可能性。

本報告提供季節性流感的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

季節性流感概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Baxter International Inc.
  • GlaxoSmithKline plc
  • Lentigen Corporation
  • Celltrion, Inc.
  • Liquidia Technologies, Inc.
  • Novartis AG
  • Novavax, Inc.
  • Crucell N.V.
  • OPKO Health, Inc.
  • Medicago Inc.
  • BioDiem Ltd
  • Colby Pharmaceutical Company
  • FluGen, Inc.
  • TechnoVax, Inc.
  • Theraclone Sciences, Inc.
  • NanoBio Corporation
  • Protein Sciences Corporation
  • VaxInnate Corporation
  • Vaxart, Inc.
  • AIMM Therapeutics B.V.
  • Cilian AG
  • AmVac AG
  • TSRL, Inc.
  • Vaxine Pty Ltd
  • AltraVax Inc.
  • Big DNA Ltd.
  • ContraFect Corporation
  • PeptiVir, Inc.
  • Pike Pharma GmbH
  • Codagenix, Inc.

治療藥的評估

  • 單獨療法的產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • seasonal influenza vaccine (trivalent)
  • influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1
  • inactivated influenza virus surface antigens vaccine
  • influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1
  • Subunit Vaccine for Seasonal Influenza
  • Influenza Vaccine (Trivalent)
  • Live Attenuated Influenza Vaccine
  • IC31 Seasonal Influenza Vaccine
  • JVRS-100 + Fluzone
  • TCN-032
  • CTP-27
  • Influenza Vaccine (Quadrivalent)
  • Seasonal Flu Vaccine
  • Monoclonal Antibody for Seasonal Influenza
  • Subunit Vaccine for Seasonal Influenza
  • Immunose FLU
  • LIQ-001
  • TAK-850
  • FluCell
  • Influenza Vaccine (Trivalent)
  • NB-1008
  • VXAA-1.1
  • VAX-2012Q
  • Seasonal Flu Vaccine
  • Flu Vaccine
  • LG-811
  • seasonal influenza vaccine (trivalent)
  • TVX-001
  • Monoclonal Antibodies to Target Hemagglutinin for Seasonal Influenza and Pandemic Influenza
  • CF-404
  • AMV-401
  • CiFlu
  • Bispecific Monoclonal Antibody for Seasonal and Pandemic Influenza
  • TSR-026
  • Seasonal Influenza Vaccine
  • IKT-041
  • influenza vaccine (trivalent)
  • Recombinant Vector Vaccine for H3N2 Seasonal Influenza
  • PVI-1000
  • Influ-nRNA
  • A-06
  • BDNA-002
  • Respiratory Syncytical Virus + Influenza Vaccine
  • VH-244
  • Pan-Flu
  • CTP-25
  • Universal Vaccine for Seasonal and Pandemic Influenza
  • TSR-462
  • Small Molecules to Inhibit Viral Polymerase for Influenza
  • seasonal influenza vaccine

開發中產品的最新趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7080IDB

Summary

Global Markets Direct's, 'Seasonal Influenza - Pipeline Review, H2 2015', provides an overview of the Seasonal Influenza's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Seasonal Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Influenza and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Seasonal Influenza
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Seasonal Influenza and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Seasonal Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Seasonal Influenza pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Seasonal Influenza
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Seasonal Influenza pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Seasonal Influenza Overview
  • Therapeutics Development
    • Pipeline Products for Seasonal Influenza - Overview
    • Pipeline Products for Seasonal Influenza - Comparative Analysis
  • Seasonal Influenza - Therapeutics under Development by Companies
  • Seasonal Influenza - Therapeutics under Investigation by Universities/Institutes
  • Seasonal Influenza - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Seasonal Influenza - Products under Development by Companies
  • Seasonal Influenza - Products under Investigation by Universities/Institutes
  • Seasonal Influenza - Companies Involved in Therapeutics Development
    • AIMM Therapeutics B.V.
    • Altimmune, Inc.
    • AltraVax Inc.
    • AmVac AG
    • Big DNA Ltd.
    • BioDiem Ltd
    • BiondVax Pharmaceuticals Ltd.
    • Celltrion, Inc.
    • Cilian AG
    • Codagenix, Inc.
    • ContraFect Corporation
    • Crucell N.V.
    • CSL Limited
    • Daiichi Sankyo Company, Limited
    • Enyo Pharma S.A.S.
    • Eurocine Vaccines AB
    • FluGen, Inc.
    • GlaxoSmithKline Plc
    • Hemispherx Biopharma, Inc.
    • Imaxio SA
    • Johnson & Johnson
    • Liquidia Technologies, Inc.
    • Medicago Inc.
    • Merck & Co., Inc.
    • Novavax, Inc.
    • OPKO Health, Inc.
    • PeptiVir, Inc.
    • Protein Sciences Corporation
    • TechnoVax, Inc.
    • Theraclone Sciences, Inc.
    • Touchlight Genetics Limited
    • TSRL, Inc.
    • Vaxart, Inc.
    • Vaxine Pty Ltd
    • VaxInnate Corporation
    • Vivaldi Biosciences Inc.
    • Zydus Cadila Healthcare Limited
  • Seasonal Influenza - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-06 - Drug Profile
    • Alferon LDO - Drug Profile
    • AMV-401 - Drug Profile
    • BDNA-002 - Drug Profile
    • Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza - Drug Profile
    • CF-404 - Drug Profile
    • CiFlu - Drug Profile
    • CR-8020 - Drug Profile
    • CTP-25 - Drug Profile
    • CTP-27 - Drug Profile
    • FluCell - Drug Profile
    • FP-01 - Drug Profile
    • IKT-041 - Drug Profile
    • IMX-313-IF - Drug Profile
    • Influ-nRNA - Drug Profile
    • influenza (quadrivalent) virus like particle vaccine - Drug Profile
    • influenza (split virion, trivalent) vaccine - Drug Profile
    • influenza (trivalent) vaccine - Drug Profile
    • influenza (trivalent) virus like particle vaccine - Drug Profile
    • influenza [serotype B] vaccine - Drug Profile
    • influenza [strain B/yamagata] (monovalent) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile
    • influenza [Strains H1N1, H3N2, influenza B] (quadrivalent) virus like particle vaccine - Drug Profile
    • influenza vaccine - Drug Profile
    • influenza vaccine - Drug Profile
    • influenza vaccine - Drug Profile
    • influenza vaccine - Drug Profile
    • JNJ-872 - Drug Profile
    • LIQ-001 - Drug Profile
    • M-001 - Drug Profile
    • MER-4101 - Drug Profile
    • Monoclonal Antibodies to Inhibit Hemagglutinin for Seasonal Influenza and Pandemic Influenza - Drug Profile
    • NB-1008 - Drug Profile
    • PVI-1000 - Drug Profile
    • respiratory syncytical virus + influenza vaccine - Drug Profile
    • seasonal influenza (quadrivalent) vaccine - Drug Profile
    • seasonal influenza (quadrivalent) vaccine - Drug Profile
    • seasonal influenza (trivalent) vaccine - Drug Profile
    • seasonal influenza (trivalent) vaccine - Drug Profile
    • seasonal influenza (trivalent, split virion) vaccine - Drug Profile
    • seasonal influenza vaccine - Drug Profile
    • seasonal influenza vaccine - Drug Profile
    • seasonal influenza vaccine - Drug Profile
    • Small Molecule to Inhibit Neuraminidase for Influenza - Drug Profile
    • Small Molecules for Influenza - Drug Profile
    • Small Molecules to Activate Sirtuin for Influenza - Drug Profile
    • TSR-026 - Drug Profile
    • TSR-462 - Drug Profile
    • TVX-001 - Drug Profile
    • VAX-2012Q - Drug Profile
    • VB126 LAIV - Drug Profile
    • VH-244 - Drug Profile
    • VN-100 - Drug Profile
    • VXAA-1.1 - Drug Profile
  • Seasonal Influenza - Recent Pipeline Updates
  • Seasonal Influenza - Dormant Projects
  • Seasonal Influenza - Discontinued Products
  • Seasonal Influenza - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Seasonal Influenza, H2 2015
  • Number of Products under Development for Seasonal Influenza - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Seasonal Influenza - Pipeline by AIMM Therapeutics B.V., H2 2015
  • Seasonal Influenza - Pipeline by Altimmune, Inc., H2 2015
  • Seasonal Influenza - Pipeline by AltraVax Inc., H2 2015
  • Seasonal Influenza - Pipeline by AmVac AG, H2 2015
  • Seasonal Influenza - Pipeline by Big DNA Ltd., H2 2015
  • Seasonal Influenza - Pipeline by BioDiem Ltd, H2 2015
  • Seasonal Influenza - Pipeline by BiondVax Pharmaceuticals Ltd., H2 2015
  • Seasonal Influenza - Pipeline by Celltrion, Inc., H2 2015
  • Seasonal Influenza - Pipeline by Cilian AG, H2 2015
  • Seasonal Influenza - Pipeline by Codagenix, Inc., H2 2015
  • Seasonal Influenza - Pipeline by ContraFect Corporation, H2 2015
  • Seasonal Influenza - Pipeline by Crucell N.V., H2 2015
  • Seasonal Influenza - Pipeline by CSL Limited, H2 2015
  • Seasonal Influenza - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Seasonal Influenza - Pipeline by Enyo Pharma S.A.S., H2 2015
  • Seasonal Influenza - Pipeline by Eurocine Vaccines AB, H2 2015
  • Seasonal Influenza - Pipeline by FluGen, Inc., H2 2015
  • Seasonal Influenza - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Seasonal Influenza - Pipeline by Hemispherx Biopharma, Inc., H2 2015
  • Seasonal Influenza - Pipeline by Imaxio SA, H2 2015
  • Seasonal Influenza - Pipeline by Johnson & Johnson, H2 2015
  • Seasonal Influenza - Pipeline by Liquidia Technologies, Inc., H2 2015
  • Seasonal Influenza - Pipeline by Medicago Inc., H2 2015
  • Seasonal Influenza - Pipeline by Merck & Co., Inc., H2 2015
  • Seasonal Influenza - Pipeline by Novavax, Inc., H2 2015
  • Seasonal Influenza - Pipeline by OPKO Health, Inc., H2 2015
  • Seasonal Influenza - Pipeline by PeptiVir, Inc., H2 2015
  • Seasonal Influenza - Pipeline by Protein Sciences Corporation, H2 2015
  • Seasonal Influenza - Pipeline by TechnoVax, Inc., H2 2015
  • Seasonal Influenza - Pipeline by Theraclone Sciences, Inc., H2 2015
  • Seasonal Influenza - Pipeline by Touchlight Genetics Limited, H2 2015
  • Seasonal Influenza - Pipeline by TSRL, Inc., H2 2015
  • Seasonal Influenza - Pipeline by Vaxart, Inc., H2 2015
  • Seasonal Influenza - Pipeline by Vaxine Pty Ltd, H2 2015
  • Seasonal Influenza - Pipeline by VaxInnate Corporation, H2 2015
  • Seasonal Influenza - Pipeline by Vivaldi Biosciences Inc., H2 2015
  • Seasonal Influenza - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Seasonal Influenza Therapeutics - Recent Pipeline Updates, H2 2015
  • Seasonal Influenza - Dormant Projects, H2 2015
  • Seasonal Influenza - Dormant Projects (Contd..1), H2 2015
  • Seasonal Influenza - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Seasonal Influenza, H2 2015
  • Number of Products under Development for Seasonal Influenza - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top